NASDAQ:NVCN Neovasc (NVCN) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free NVCN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$30.03▼$30.0350-Day Range$29.03▼$30.0352-Week Range$4.59▼$30.07Volume1 shsAverage Volume56,993 shsMarket Capitalization$82.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neovasc alerts: Email Address Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. About Neovasc Stock (NASDAQ:NVCN)Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.Read More Ad Porter & CompanyKiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.I have uncovered a bombshell that changes everything… and threatens everything. NVCN Stock News HeadlinesApril 15, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc down on Tuesday (NVCN)April 11, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc up on Monday (NVCN)June 18, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.March 31, 2023 | finance.yahoo.comNeovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comNeovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearMarch 6, 2023 | finance.yahoo.comNeovasc Shareholders Approve Acquisition by Shockwave MedicalFebruary 1, 2023 | finance.yahoo.comNeovasc Announces German Reimbursement RenewalJanuary 11, 2023 | finance.yahoo.comNeovasc (NVCN) is on the Move, Here's Why the Trend Could be SustainableJune 18, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenBiden cannot lose this election. A bombshell new documentary exposes how the D.C establishment has engineered an “electoral failsafe” that all but guarantees Democratic victory… not just in 2024 but every future election.December 26, 2022 | finance.yahoo.comRecent Price Trend in Neovasc (NVCN) is Your Friend, Here's WhyDecember 21, 2022 | finance.yahoo.com3 Medical Instruments Stocks on Recovery Path After Dismal 2022November 28, 2022 | finance.yahoo.comNeovasc Announces Progress on COSIRA-II Clinical TrialNovember 17, 2022 | finance.yahoo.comNeovasc Third Quarter 2022 Earnings: Misses ExpectationsNovember 10, 2022 | finance.yahoo.comNeovasc Announces Third Quarter Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comNeovasc to Report Third Quarter Financial Results on November 10, 2022September 30, 2022 | proactiveinvestors.comNeovasc uses conference to announce positive interim clinical data from Neovasc Reducer use - Proactive Investors USASeptember 20, 2022 | streetinsider.comForm 6-K NEOVASC INC For: Sep 20 - StreetInsider.comSeptember 20, 2022 | seekingalpha.comNeovasc puts further development of its Tiara transcatheter treatment on hold - Seeking AlphaSeptember 20, 2022 | globenewswire.comNeovasc Provides Corporate Update Following Clinical Data Release - GlobeNewswireSeptember 17, 2022 | finance.yahoo.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - Yahoo FinanceSeptember 16, 2022 | globenewswire.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - GlobeNewswireSeptember 15, 2022 | globenewswire.comNeovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comNeovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory AnginaSeptember 8, 2022 | marketscreener.comNeovasc Announces Participation at Transcatheter Cardiovascular Therapeutics Conf - Marketscreener.comSeptember 8, 2022 | finance.yahoo.comScaleFlux Announces Partnership with TD SYNNEX to Increase Market Footprint for Next-generation SSDs - Yahoo FinanceSeptember 8, 2022 | finance.yahoo.com32 Shipping Companies Presenting at Capital Link’s 14th Annual New York Maritime Forum September 21, 2022 in New York City - Yahoo FinanceSeptember 8, 2022 | globenewswire.comNeovasc Announces Key Events at TCT 2022 - GlobeNewswireSee More Headlines Receive NVCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVCN CUSIPN/A CIK1399708 Webwww.neovasc.com Phone(604) 270-4344Fax604-270-4384Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-1,082.92% Pretax Margin-1,082.26% Return on Equity-127.25% Return on Assets-80.31% Debt Debt-to-Equity Ratio0.80 Current Ratio2.96 Quick Ratio2.85 Sales & Book Value Annual Sales$3.81 million Price / Sales21.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book5.20Miscellaneous Outstanding Shares2,740,000Free FloatN/AMarket Cap$82.28 million OptionableNot Optionable Beta1.70 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesFredericus Antonius ColenPresident, Chief Executive Officer & DirectorBill LittleChief Operating OfficerChristopher ClarkChief Financial Officer & SecretarySarah GallagherVice President-Clinical AffairsShmuel BanaiMedical DirectorKey CompetitorsOraSure TechnologiesNASDAQ:OSURCerusNASDAQ:CERSOrchestra BioMedNASDAQ:OBIOTactile Systems TechnologyNASDAQ:TCMDFractyl HealthNASDAQ:GUTSView All Competitors NVCN Stock Analysis - Frequently Asked Questions How were Neovasc's earnings last quarter? Neovasc Inc. (NASDAQ:NVCN) announced its quarterly earnings results on Tuesday, November, 9th. The medical equipment provider reported ($2.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.25) by $0.50. The medical equipment provider had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.20 million. Neovasc had a negative net margin of 1,082.92% and a negative trailing twelve-month return on equity of 127.25%. During the same period in the previous year, the business earned ($12.75) EPS. When did Neovasc's stock split? Neovasc shares reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Palatin Technologies (PTN), Amarin (AMRN). This page (NASDAQ:NVCN) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | Sponsoredwhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's alway...Prosper Trading Academy | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neovasc Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neovasc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.